| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies.
|
Clin Cancer Res
|
2006
|
2.33
|
|
2
|
Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer.
|
J Clin Oncol
|
2005
|
1.86
|
|
3
|
Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours.
|
Eur J Cancer
|
2005
|
1.42
|
|
4
|
Targeting protein-protein interactions: suppression of Stat3 dimerization with rationally designed small-molecule, nonpeptidic SH2 domain binders.
|
Chembiochem
|
2008
|
1.21
|
|
5
|
Randomized phase I pharmacokinetic study of ipilimumab with or without one of two different chemotherapy regimens in patients with untreated advanced melanoma.
|
Cancer Immun
|
2013
|
1.17
|
|
6
|
Exposure-response relationships of the efficacy and safety of ipilimumab in patients with advanced melanoma.
|
Clin Cancer Res
|
2013
|
1.04
|
|
7
|
Clinically relevant QTc prolongation is not associated with current dose schedules of LBH589 (panobinostat).
|
J Clin Oncol
|
2008
|
0.85
|
|
8
|
Metabolism and disposition of vatalanib (PTK787/ZK-222584) in cancer patients.
|
Drug Metab Dispos
|
2006
|
0.84
|
|
9
|
PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasia.
|
Leuk Res
|
2007
|
0.83
|
|
10
|
Pharmacokinetics, pharmacodynamics, and immunogenicity of belatacept in adult kidney transplant recipients.
|
Clin Drug Investig
|
2014
|
0.81
|
|
11
|
Model-based clinical pharmacology profiling of ipilimumab in patients with advanced melanoma.
|
Br J Clin Pharmacol
|
2014
|
0.81
|
|
12
|
Inhibitory effect of ketoconazole on the pharmacokinetics of a multireceptor tyrosine kinase inhibitor BMS-690514 in healthy participants: assessing the mechanism of the interaction with physiologically-based pharmacokinetic simulations.
|
J Clin Pharmacol
|
2013
|
0.81
|
|
13
|
Silver-promoted desilylation catalyzed by ortho- and allosteric cucurbiturils.
|
Org Lett
|
2010
|
0.81
|
|
14
|
Unusual amount of (-)-mesquitol from the heartwood of Prosopis juliflora.
|
Nat Prod Res
|
2009
|
0.79
|
|
15
|
Metabolism, excretion, and pharmacokinetics of oral brivanib in patients with advanced or metastatic solid tumors.
|
Drug Metab Dispos
|
2010
|
0.79
|
|
16
|
Stabilization of cucurbituril/guest assemblies via long-range Coulombic and CH···O interactions.
|
J Am Chem Soc
|
2014
|
0.78
|
|
17
|
Cucurbituril slippage: translation is a complex motion.
|
Org Lett
|
2010
|
0.77
|
|
18
|
The effects of liver impairment on the pharmacokinetics of brivanib, a dual inhibitor of fibroblast growth factor receptor and vascular endothelial growth factor receptor tyrosine kinases.
|
Cancer Chemother Pharmacol
|
2013
|
0.76
|
|
19
|
Formation and stabilization of silver nanoparticles with cucurbit[n]urils (n = 5-8) and cucurbituril-based pseudorotaxanes in aqueous medium.
|
Langmuir
|
2011
|
0.76
|
|
20
|
A pilot study to evaluate the pharmacokinetics of sibutramine in healthy subjects under fasting and fed conditions.
|
J Pharm Pharm Sci
|
2004
|
0.76
|
|
21
|
Lack of food effect on single-dose pharmacokinetics of brivanib, and safety and efficacy following multiple doses in subjects with advanced or metastatic solid tumors.
|
Cancer Chemother Pharmacol
|
2011
|
0.75
|
|
22
|
Metabolic chiral inversion of brivanib and its relevance to safety and pharmacology.
|
Drug Metab Dispos
|
2012
|
0.75
|
|
23
|
Lactic acid/wood-based composite material. Part 1: Synthesis and characterization.
|
Bioresour Technol
|
2009
|
0.75
|
|
24
|
Cucurbituril slippage: cations as supramolecular lubricants.
|
Org Lett
|
2012
|
0.75
|
|
25
|
Lack of effect of brivanib on the pharmacokinetics of midazolam, a CYP3A4 substrate, administered intravenously and orally in healthy participants.
|
J Clin Pharmacol
|
2011
|
0.75
|
|
26
|
Lactic acid/wood-based composite material. Part 2: Physical and mechanical performance.
|
Bioresour Technol
|
2009
|
0.75
|
|
27
|
Metabolism and disposition of [14C]brivanib alaninate after oral administration to rats, monkeys, and humans.
|
Drug Metab Dispos
|
2011
|
0.75
|
|
28
|
Subtle "supramolecular buttressing effects" in Cucurbit[7]uril/guest assemblies.
|
Org Biomol Chem
|
2013
|
0.75
|